BMO Capital Markets reiterated their outperform rating on shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) in a research note published on Wednesday morning. BMO Capital Markets currently has a $13.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $12.00.
TTPH has been the topic of a number of other research reports. HC Wainwright began coverage on shares of Tetraphase Pharmaceuticals in a report on Tuesday, July 11th. They issued a buy rating and a $15.00 price objective on the stock. Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a hold rating to a buy rating and boosted their price objective for the stock from $8.00 to $15.00 in a report on Wednesday. Finally, Zacks Investment Research lowered shares of Tetraphase Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, May 10th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $10.25.
Shares of Tetraphase Pharmaceuticals (TTPH) traded down 11.68% during mid-day trading on Wednesday, hitting $6.96. The stock had a trading volume of 3,882,443 shares. Tetraphase Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.93. The stock’s market cap is $264.17 million. The company’s 50 day moving average price is $7.48 and its 200 day moving average price is $6.84.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by $0.19. Tetraphase Pharmaceuticals had a negative return on equity of 60.55% and a negative net margin of 1,932.24%. The firm had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.46 million. During the same quarter in the prior year, the firm earned ($0.46) EPS. The business’s quarterly revenue was down 24.5% compared to the same quarter last year. Equities research analysts predict that Tetraphase Pharmaceuticals will post ($2.66) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Receives Outperform Rating from BMO Capital Markets” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/07/27/tetraphase-pharmaceuticals-inc-nasdaqttph-receives-outperform-rating-from-bmo-capital-markets.html.
Several large investors have recently made changes to their positions in TTPH. GSA Capital Partners LLP increased its stake in shares of Tetraphase Pharmaceuticals by 90.2% in the fourth quarter. GSA Capital Partners LLP now owns 33,600 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 15,931 shares in the last quarter. Wade G W & Inc. acquired a new stake in shares of Tetraphase Pharmaceuticals during the first quarter worth $138,000. Teza Capital Management LLC increased its stake in shares of Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,281 shares in the last quarter. Citadel Advisors LLC increased its stake in shares of Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 2,496 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Tetraphase Pharmaceuticals during the fourth quarter worth $156,000. 46.24% of the stock is owned by institutional investors and hedge funds.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tetraphase Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.